JP2012529535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529535A5 JP2012529535A5 JP2012515123A JP2012515123A JP2012529535A5 JP 2012529535 A5 JP2012529535 A5 JP 2012529535A5 JP 2012515123 A JP2012515123 A JP 2012515123A JP 2012515123 A JP2012515123 A JP 2012515123A JP 2012529535 A5 JP2012529535 A5 JP 2012529535A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- alkoxy
- substituted
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 264
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 131
- -1 —OH Chemical group 0.000 claims 74
- 125000003545 alkoxy group Chemical group 0.000 claims 56
- 125000005843 halogen group Chemical group 0.000 claims 50
- 125000001424 substituent group Chemical group 0.000 claims 47
- 125000000623 heterocyclic group Chemical group 0.000 claims 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims 28
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 21
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 17
- 229910052799 carbon Inorganic materials 0.000 claims 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 15
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 14
- 125000004076 pyridyl group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 12
- 125000001624 naphthyl group Chemical group 0.000 claims 11
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 11
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 10
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 10
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 9
- 125000004122 cyclic group Chemical group 0.000 claims 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 125000001041 indolyl group Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000002541 furyl group Chemical group 0.000 claims 7
- 125000002883 imidazolyl group Chemical group 0.000 claims 7
- 125000002757 morpholinyl group Chemical group 0.000 claims 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 125000000335 thiazolyl group Chemical group 0.000 claims 6
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 5
- 235000010290 biphenyl Nutrition 0.000 claims 5
- 239000004305 biphenyl Substances 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000001207 fluorophenyl group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000003386 piperidinyl group Chemical group 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004965 chloroalkyl group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 0 C*(C(*=C(C)N)=C(C(*)=C)C(*(C)(C)*)=O)c1ccc(C)c(C)c1 Chemical compound C*(C(*=C(C)N)=C(C(*)=C)C(*(C)(C)*)=O)c1ccc(C)c(C)c1 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18641709P | 2009-06-12 | 2009-06-12 | |
| US61/186,417 | 2009-06-12 | ||
| PCT/US2010/038079 WO2010144647A1 (en) | 2009-06-12 | 2010-06-10 | Nicotinamide compounds useful as kinase modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012529535A JP2012529535A (ja) | 2012-11-22 |
| JP2012529535A5 true JP2012529535A5 (enExample) | 2013-06-27 |
Family
ID=42543320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012515123A Pending JP2012529535A (ja) | 2009-06-12 | 2010-06-10 | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8586751B2 (enExample) |
| EP (1) | EP2440204B1 (enExample) |
| JP (1) | JP2012529535A (enExample) |
| CN (1) | CN102458402B (enExample) |
| ES (1) | ES2444777T3 (enExample) |
| WO (1) | WO2010144647A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8110581B2 (en) | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
| JP5744021B2 (ja) | 2010-06-30 | 2015-07-01 | 富士フイルム株式会社 | 新規なニコチンアミド誘導体またはその塩 |
| AU2011323484B2 (en) * | 2010-11-01 | 2016-10-06 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as Syk modulators |
| US9073947B2 (en) | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| CN103073508B (zh) * | 2011-10-25 | 2016-06-01 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
| US9782406B2 (en) | 2011-10-25 | 2017-10-10 | Peking University Shenzhen Graduate School | Kinase inhibitor and method for treatment of related diseases |
| DK2799431T3 (en) * | 2011-12-28 | 2018-03-26 | Fujifilm Corp | Hitherto unknown nicotinamide derivatives or salts thereof |
| ES2686500T3 (es) | 2012-01-13 | 2018-10-18 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas |
| EP2802579B1 (en) | 2012-01-13 | 2016-04-13 | Bristol-Myers Squibb Company | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| WO2013106614A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| CN104302640A (zh) * | 2012-03-16 | 2015-01-21 | 埃克希金医药品有限公司 | 3,5-二氨基吡唑激酶抑制剂 |
| WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| CN104662018B (zh) | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
| HK1206073A1 (en) | 2012-07-24 | 2015-12-31 | 药品循环有限责任公司 | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| MX2015004801A (es) * | 2012-10-19 | 2015-08-14 | Hoffmann La Roche | Inhibidores de la syk. |
| AU2013341200A1 (en) | 2012-11-08 | 2015-07-02 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| CA2890935A1 (en) * | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha. |
| CN104781251B (zh) | 2012-11-08 | 2016-12-14 | 百时美施贵宝公司 | 可作为激酶调节剂的经双环杂环取代的吡啶基化合物 |
| CN104109127B (zh) * | 2013-04-19 | 2019-11-05 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
| PL2989106T3 (pl) | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Połączone związki heterocykliczne jako inhibitory kinazy białkowej |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| RU2677884C2 (ru) * | 2013-09-30 | 2019-01-22 | Гуанчжоу Иннокэа Фарма Тек Ко., Лтд. | Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний |
| US10329270B2 (en) * | 2013-10-21 | 2019-06-25 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| GB201319277D0 (en) * | 2013-10-31 | 2013-12-18 | Akthelia Pharmaceuticals | A new class of inducers of antimicrobial compounds |
| AU2014360446A1 (en) | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
| TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| CU24395B1 (es) * | 2014-03-17 | 2019-04-04 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| MX393057B (es) | 2014-10-24 | 2025-03-24 | Bristol Myers Squibb Co | Compuestos de indol carboxamida útiles como inhibidores de cinasas. |
| EP3042903B1 (en) | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| CN104672218A (zh) * | 2015-02-13 | 2015-06-03 | 佛山市赛维斯医药科技有限公司 | 含葡萄糖酰胺结构的葡萄糖激酶活化剂、制备方法及其在治疗2型糖尿病上的用途 |
| CN104672219A (zh) * | 2015-02-13 | 2015-06-03 | 佛山市赛维斯医药科技有限公司 | 一类含葡萄糖酰胺结构的葡萄糖激酶活化剂及其用途 |
| EP3313844B1 (en) | 2015-06-24 | 2020-08-26 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| TW201713655A (zh) | 2015-06-24 | 2017-04-16 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| CN107849039B (zh) | 2015-06-24 | 2020-07-03 | 百时美施贵宝公司 | 经杂芳基取代的氨基吡啶化合物 |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| IL293319B1 (en) | 2016-08-16 | 2026-01-01 | Beone Medicines Ltd | Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| CN109982687A (zh) | 2016-09-19 | 2019-07-05 | 梅制药公司 | 联合疗法 |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| CA3062602A1 (en) | 2017-05-11 | 2018-11-15 | Bristol-Myers Squibb Company | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| KR102613433B1 (ko) * | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| EP3867242A1 (en) * | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| WO2020106305A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
| EP3883552B1 (en) * | 2018-11-20 | 2025-04-09 | NFlection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
| CN113473986B (zh) | 2018-11-20 | 2024-10-11 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病萘啶酮苯胺化合物 |
| EP3924350A1 (en) | 2019-02-13 | 2021-12-22 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3981399A4 (en) | 2019-06-10 | 2023-05-31 | BeiGene Switzerland GmbH | ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF |
| JP7620611B2 (ja) | 2019-07-18 | 2025-01-23 | ブリストル－マイヤーズ スクイブ カンパニー | ＩＲＡＫ４阻害剤として有用なピラゾロ［３，４－ｄ］ピロロ［１，２－ｂ］ピリダジニル化合物 |
| WO2021011724A1 (en) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| EP4010317B1 (en) | 2019-08-06 | 2024-06-19 | Bristol-Myers Squibb Company | Bicyclic heterocyclic compounds useful as irak4 inhibitors |
| CN114206874B (zh) | 2019-08-13 | 2024-08-02 | 百时美施贵宝公司 | 可用作irak4抑制剂的双环杂芳基化合物 |
| CA3160713A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| WO2021158495A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| EP4100408B1 (en) | 2020-02-03 | 2024-02-28 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| CN111909053B (zh) * | 2020-08-06 | 2022-12-06 | 湖北省生物农药工程研究中心 | 基于二芳胺单元的酰胺类衍生物及其制备方法和应用 |
| CN117157065A (zh) | 2021-01-21 | 2023-12-01 | 恩福莱克逊治疗有限公司 | 吡咯并吡啶-苯胺化合物的晶型 |
| US20240252665A1 (en) * | 2021-06-02 | 2024-08-01 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Chemical coupling linker and use thereof |
| KR20240029070A (ko) * | 2021-07-01 | 2024-03-05 | 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 | 브루톤 티로신 키나아제, 이의 돌연변이체 분해제, 조성물 및 응용 |
| MX2024004899A (es) | 2021-10-26 | 2024-05-24 | Nurix Therapeutics Inc | Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk. |
| CR20240325A (es) * | 2022-01-07 | 2024-11-22 | Chugai Pharmaceutical Co Ltd | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| US12630562B2 (en) * | 2024-08-07 | 2026-05-19 | Arcus Biosciences, Inc. | Piperidylurea compounds and methods of use thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL132603C (enExample) | 1964-08-29 | |||
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| FR2665159B1 (fr) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| US5104877A (en) | 1991-02-25 | 1992-04-14 | Abbott Laboratories | Psoriasis treatment |
| US5691364A (en) | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| US5972975A (en) | 1995-12-08 | 1999-10-26 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| ZA977427B (en) | 1996-09-04 | 1998-03-02 | Dainippon Pharmaceutical Co | 2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same. |
| SI1028950T1 (en) | 1997-10-28 | 2003-08-31 | Warner-Lambert Company Llc | 7-substituted quinazolin-2,4-diones useful as antibacterial agents |
| ATE401312T1 (de) | 1997-12-15 | 2008-08-15 | Astellas Pharma Inc | Pyrimidin-5-carboxamid-derivate |
| IL144717A0 (en) | 1999-02-24 | 2002-06-30 | Hoffmann La Roche | Phenyl-and pyridinyl derivatives |
| EP1184376B1 (en) * | 1999-06-09 | 2005-02-02 | Yamanouchi Pharmaceutical Co. Ltd. | Novel heterocyclic carboxamide derivatives |
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| CA2383466C (en) | 1999-09-16 | 2009-08-25 | Tanabe Seiyaku Co., Ltd. | Aromatic nitrogen-containing 6-membered cyclic compounds |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| WO2002030357A2 (en) | 2000-10-11 | 2002-04-18 | Chemocentryx, Inc. | Compounds and methods for modulating ccr4 function |
| JP2002193938A (ja) | 2000-12-01 | 2002-07-10 | Bayer Ag | ４−アリールピリジン誘導体 |
| JP4178816B2 (ja) | 2001-03-15 | 2008-11-12 | 田辺三菱製薬株式会社 | 医薬組成物 |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| EP1492784A4 (en) | 2002-03-28 | 2006-03-29 | Merck & Co Inc | SUBSTITUTED 2,3-DIPHENYLPYRIDINES |
| WO2004024159A1 (en) | 2002-09-10 | 2004-03-25 | Scios Inc. | INHIBITORS OF TFGβ |
| US20040116479A1 (en) | 2002-10-04 | 2004-06-17 | Fortuna Haviv | Method of inhibiting angiogenesis |
| EP1583531B1 (en) | 2003-01-16 | 2007-04-18 | SB Pharmco Puerto Rico Inc | Heteroaryl-substituted pyrrolo[2, 3- b]pyridine derivatives as crf receptor antagonists |
| EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| US7459460B2 (en) * | 2003-05-28 | 2008-12-02 | Bristol-Myers Squibb Company | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| US7329664B2 (en) | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| EP1678146A1 (en) | 2003-10-23 | 2006-07-12 | Pharmacia Corporation | Pyrimidine compounds for the treatment of inflammation |
| WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| ES2364340T3 (es) | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| EP1751136B1 (en) | 2004-05-07 | 2014-07-02 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| JP2008504294A (ja) | 2004-06-25 | 2008-02-14 | アムジエン・インコーポレーテツド | サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール |
| US20060069110A1 (en) | 2004-09-27 | 2006-03-30 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP2008519843A (ja) | 2004-11-10 | 2008-06-12 | シージーアイ ファーマスーティカル インコーポレーテッド | 特定のイミダゾ［１，２−ａ］ビラジン−８−イラミンズ、その生成方法及びそれに関する使用方法 |
| GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| AU2006214378A1 (en) | 2005-02-16 | 2006-08-24 | Pharmacopeia, Inc. | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity |
| AU2006223409B2 (en) | 2005-03-10 | 2011-07-21 | Gilead Connecticut, Inc. | Certain substituted amides, method of making, and method of use thereof |
| ATE432260T1 (de) | 2005-03-28 | 2009-06-15 | Boehringer Ingelheim Int | Pyridinderivate als pkc-theta-hemmer |
| EP1879564B1 (en) | 2005-04-07 | 2009-12-23 | Astrum Therapeutics Pty, Ltd. | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus |
| WO2006124897A2 (en) | 2005-05-13 | 2006-11-23 | Lexicon Genetics Incorporated | Methods and compositions for improving cognition |
| CN101193635A (zh) | 2005-05-13 | 2008-06-04 | 莱西肯医药有限公司 | 多环化合物及其使用方法 |
| US20090203744A1 (en) | 2005-07-29 | 2009-08-13 | Pande Y Surendrakumar Satyanarayan | Novel pyridine derivatives |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20090131420A1 (en) | 2005-10-07 | 2009-05-21 | Pandey Surendrakumar S | Novel Heterocyclic Analogs of Biphenyl Ethers |
| WO2007045462A2 (de) | 2005-10-19 | 2007-04-26 | Grünenthal GmbH | Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln |
| BRPI0619208A2 (pt) | 2005-11-30 | 2011-09-20 | Astellas Pharma Inc | derivado de 2-aminobenzamida c07d 307/14 c07d 307/22 c07d 309/14 c07d 319/12 c07d 401/12 c07d 405/12 c07d 413/12 c07d 417/12 |
| EA018128B1 (ru) | 2006-01-23 | 2013-05-30 | Амген Инк. | Модуляторы аурора киназы, способы их получения и их применение |
| US20070208164A1 (en) | 2006-02-27 | 2007-09-06 | Wyeth | Methods of synthesizing radiolabeled 3-cyano[14C]quinolines |
| CA2647338A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors-3 |
| ES2645095T3 (es) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
| JP2008013499A (ja) * | 2006-07-06 | 2008-01-24 | Sankyo Co Ltd | ５−シアノニコチンアミド誘導体 |
| GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
| WO2008016643A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| US7939548B2 (en) | 2006-08-02 | 2011-05-10 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| JP2009545630A (ja) | 2006-08-04 | 2009-12-24 | プリーシス・ファーマシューティカルズ・インコーポレイテッド | 化合物 |
| WO2008024963A1 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Benzene, pyridine, and pyridazine derivatives |
| JP2010502751A (ja) | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ，インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
| WO2008044713A1 (fr) | 2006-10-10 | 2008-04-17 | Nihon Nohyaku Co., Ltd. | Dérivé de pyridinecarboxanilide substitué ou un de ses sels, agent agricole ou horticole et utilisation de celui-ci |
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| WO2008079294A1 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| FR2921657A1 (fr) | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
| JP5600063B2 (ja) | 2007-10-19 | 2014-10-01 | セルジーン アビロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
-
2010
- 2010-06-10 CN CN2010800346423A patent/CN102458402B/zh not_active Expired - Fee Related
- 2010-06-10 ES ES10724657.1T patent/ES2444777T3/es active Active
- 2010-06-10 WO PCT/US2010/038079 patent/WO2010144647A1/en not_active Ceased
- 2010-06-10 US US13/377,157 patent/US8586751B2/en active Active
- 2010-06-10 JP JP2012515123A patent/JP2012529535A/ja active Pending
- 2010-06-10 EP EP10724657.1A patent/EP2440204B1/en not_active Not-in-force